AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY26 results · Oct–Dec 2025
AstraZeneca Pharma India reported revenue from operations of ₹611.57 crore (up 38.9% from Q3 FY25) and net profit of ₹32.59 crore (up 5.6% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a standalone basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 611.57 | 440.29 | +38.9% | 559.09 | +9.4% |
| Other income | 5.13 | 7.98 | −35.7% | 6.17 | −16.9% |
| Total income | 616.70 | 448.27 | +37.6% | 565.26 | +9.1% |
| Profit before tax | 46.54 | 42.02 | +10.8% | 72.82 | −36.1% |
| Net profit for the period | 32.59 | 30.85 | +5.6% | 54.22 | −39.9% |
| EPS, basic (₹) | 13.04 | 12.34 | +5.7% | 21.69 | −39.9% |
| Net margin (%) | 5.3 | 7.0 | 9.7 |
Standalone
- Filed with BSE
- 11 Feb 2026, 19:24 IST
- Board meeting
- 11 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE